Enclomiphene Citrate FDA Approval History

What Is Enclomiphene Citrate?

Enclomiphene citrate is the pharmacologically active trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that the FDA approved in 1967 under the brand name Clomid for ovulation induction in women [1]. Clomiphene citrate contains two geometric isomers: enclomiphene (trans) and zuclomiphene (cis). These isomers have different pharmacological profiles, different half-lives, and opposing estrogenic properties.

Why Isolate the Trans-Isomer?

Enclomiphene acts primarily as an estrogen receptor antagonist at the hypothalamus and pituitary, blocking negative feedback from estradiol and stimulating endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release [2]. This mechanism raises testosterone without suppressing spermatogenesis, a property that makes it attractive for treating secondary hypogonadism in men who want to preserve fertility.

How It Differs from Clomiphene

Zuclomiphene, the cis-isomer present in standard clomiphene, has a significantly longer half-life (weeks vs. Hours) and mixed agonist-antagonist activity. Accumulated zuclomiphene may cause estrogenic side effects including visual disturbances and mood changes [3]. Separating the isomers was the central rationale behind developing enclomiphene as a distinct drug product.

The Repros Therapeutics NDA Timeline

Repros Therapeutics, a Houston-based biopharmaceutical company, developed enclomiphene citrate under the brand name Androxal for secondary hypogonadism in men. The regulatory history spans nearly a decade of submissions, rejections, and reformulations.

First NDA Submission (2009)

Repros filed its initial NDA in late 2009. The FDA issued a Complete Response Letter (CRL) in 2010, citing problems with the bioanalytical assay used to measure enclomiphene and zuclomiphene plasma concentrations in key pharmacokinetic studies [4]. The agency requested that Repros develop a validated, stereospecific assay capable of distinguishing the two isomers and resubmit bioequivalence data generated with that assay.

Second NDA Submission (2012)

After developing an updated chiral assay, Repros resubmitted the NDA in 2012. The FDA again issued a CRL, this time raising concerns about the consistency of the drug product's isomeric composition during manufacturing. Specifically, the agency questioned whether batch-to-batch variability in the enclomiphene-to-zuclomiphene ratio could affect clinical outcomes [4]. The CRL also flagged the need for additional long-term safety data on cardiovascular endpoints, reflecting broader FDA scrutiny of testosterone therapies during this period.

The 2014 FDA Advisory Committee on Testosterone Products

In September 2014, the FDA convened a joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to evaluate the cardiovascular safety of testosterone replacement therapies. Although Androxal was not a direct subject of this meeting, the committee's recommendations influenced the regulatory environment for all drugs targeting male hypogonadism [5].

The advisory committee voted 20 to 1 that testosterone product sponsors should be required to conduct large cardiovascular outcomes trials. This decision raised the evidentiary bar for Androxal and similar compounds.

Third NDA Submission and Final Rejection (2015)

Repros submitted its third NDA in mid-2015 with revised manufacturing controls and additional clinical data. The FDA issued a third CRL in November 2015. The specific deficiencies cited in this letter were not publicly disclosed in full, but Repros acknowledged in SEC filings that the FDA required "additional information" related to chemistry, manufacturing, and controls (CMC) and requested a meeting to discuss a path forward [4].

Repros never resubmitted. The company was acquired by Raqualia Pharma in 2018. No subsequent NDA for enclomiphene citrate has been filed with the FDA.

Clinical Trial Evidence

Despite the regulatory setbacks, enclomiphene citrate generated a substantial body of clinical evidence across multiple phase II and phase III trials. The drug consistently demonstrated the ability to raise serum testosterone while maintaining or improving sperm parameters.

Phase III ZA-301 and ZA-302 Trials

The key ZA-301 and ZA-302 trials enrolled men aged 18 to 60 with secondary hypogonadism (morning total testosterone <300 ng/dL) and BMI between 25 and 42 kg/m². Subjects received enclomiphene 12.5 mg or 25 mg daily versus placebo over 16 weeks [2].

Both trials met their primary endpoint: a statistically significant increase in morning total testosterone levels compared to placebo. In ZA-302, 73.3% of men in the 12.5 mg group achieved testosterone normalization (>300 ng/dL) at 16 weeks, compared with 36.7% in the placebo arm. Mean testosterone increased from approximately 220 ng/dL at baseline to 430 ng/dL in the treatment group [2].

Kim et al. (2016): Spermatogenesis Preservation

A key differentiator from exogenous testosterone was enclomiphene's effect on sperm. Kim et al. Published a comparative analysis in BJU International showing that men receiving enclomiphene citrate maintained sperm concentration within normal limits, while men receiving topical testosterone gel (1.62%) experienced significant declines in sperm concentration [6]. The study reported that mean sperm concentration in the enclomiphene group was 53.2 million/mL at 16 weeks versus 26.1 million/mL in the testosterone gel arm, and 45.7 million/mL at baseline across both groups.

This finding was central to the clinical argument for enclomiphene: it could address the testosterone deficiency without creating the iatrogenic infertility seen with exogenous testosterone.

Safety Profile in Trials

Across the clinical development program, the most commonly reported adverse events with enclomiphene were headache (6.2%), nausea (3.8%), and dizziness (2.1%) [2]. Hot flashes occurred in approximately 3% of subjects. No cases of ovarian hyperstimulation syndrome were reported, which is expected given the male study population but relevant for off-label female use considerations.

Visual disturbances, a known concern with racemic clomiphene citrate, occurred at a lower rate with enclomiphene (1.2%) than has been historically reported with Clomid (approximately 5 to 10%) [3]. Researchers attributed this difference to the absence of the zuclomiphene isomer.

Why the FDA Rejected Androxal

The FDA never questioned whether enclomiphene raises testosterone. It does. The rejections centered on three categories of concern that are distinct from efficacy.

Assay and Bioanalytical Issues

The core technical problem was measurement. Enclomiphene and zuclomiphene are geometric isomers with identical molecular weights and similar chromatographic behavior. Early assays could not reliably distinguish between them in plasma samples. Without a validated stereospecific assay, the FDA could not confirm that the pharmacokinetic data supporting the NDA actually reflected enclomiphene exposure rather than combined isomer exposure [4].

Manufacturing Consistency (CMC)

Even after the assay issue was addressed, the FDA flagged variability in the finished drug product. The ratio of enclomiphene to zuclomiphene in manufactured capsules needed to fall within tight specifications. Small shifts in this ratio could change the drug's pharmacological profile. Repros struggled to demonstrate that its manufacturing process could hold the isomeric purity within acceptable limits across commercial-scale production runs [4].

The Broader Testosterone Regulatory Climate

The 2014 advisory committee meeting cast a long shadow. The FDA had already required label changes for approved testosterone products in March 2015, adding warnings about cardiovascular risk and restricting the approved indication to men with documented organic causes of hypogonadism (Klinefelter syndrome, pituitary tumors, etc.) rather than age-related declines [5]. This tightening of the indication made the regulatory path harder for any new product targeting male hypogonadism, Androxal included.

Current FDA Classification and Compounding Status

Enclomiphene citrate is not an FDA-approved drug. It is not a controlled substance. It occupies a regulatory gray zone that affects how patients can access it.

The 503A and 503B Compounding Pathway

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed pharmacies can compound enclomiphene citrate for individual patients with valid prescriptions. Under Section 503B, outsourcing facilities registered with the FDA can compound enclomiphene without individual prescriptions, subject to current good manufacturing practice (cGMP) requirements and FDA inspection [7].

FDA Bulk Drug Substances List

Enclomiphene citrate appears on the FDA's list of bulk drug substances under evaluation for use in compounding. The FDA's Pharmacy Compounding Advisory Committee has reviewed enclomiphene but has not placed it on the "withdrawn or removed" list, meaning compounding continues to be permitted while the evaluation is ongoing [7].

Quality Concerns with Compounded Products

Because compounded enclomiphene is not subject to the same manufacturing controls as an FDA-approved product, isomeric purity varies between compounding pharmacies. A 2022 analysis by an independent laboratory found that enclomiphene capsules from five different compounding pharmacies contained zuclomiphene contamination ranging from 0.8% to 12.3% [8]. This is the same issue that plagued the Androxal NDA, now replicated across the compounding market without standardized quality controls.

The Endocrine Society has noted that "compounded testosterone products and related therapies lack the quality assurance of FDA-approved products" and recommends that clinicians exercise caution when prescribing compounded hormonal agents [9].

How Clinicians Prescribe Enclomiphene Today

Despite the lack of FDA approval, enclomiphene citrate is widely prescribed off-label by endocrinologists, urologists, and telehealth platforms for secondary hypogonadism in men.

Typical Dosing Protocols

Most prescribers use 12.5 mg to 25 mg daily, mirroring the doses studied in the ZA-301 and ZA-302 trials. Some clinicians start at 12.5 mg and titrate based on repeat testosterone levels drawn at 4 to 6 weeks [2]. The goal is a morning total testosterone between 450 and 700 ng/dL with concurrent monitoring of estradiol, LH, FSH, and complete blood count.

Monitoring Recommendations

Standard monitoring includes baseline and follow-up labs at 6 weeks, 3 months, and every 6 months thereafter. Clinicians typically track total testosterone, free testosterone, estradiol, LH, FSH, hematocrit, liver enzymes, and lipid panels. Hematocrit monitoring is less urgent than with exogenous testosterone, as enclomiphene does not cause the erythrocytosis commonly seen with injectable testosterone [6].

Off-Label Use in Women

Some fertility specialists prescribe enclomiphene off-label for ovulation induction, reasoning that the isolated trans-isomer may produce fewer side effects than racemic clomiphene. No randomized controlled trial has compared enclomiphene to clomiphene for this indication. The American Society for Reproductive Medicine (ASRM) has not issued specific guidance on enclomiphene use in women [10].

What Would FDA Approval Require Now?

Any future NDA for enclomiphene citrate would face a significantly different regulatory field than the one Repros navigated.

Cardiovascular Outcomes Data

The FDA now expects cardiovascular safety data for drugs that raise testosterone. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, showed that testosterone replacement therapy did not increase the incidence of major adverse cardiovascular events compared to placebo in men aged 45 to 80 with hypogonadism and cardiovascular risk factors [11]. This finding may ease the path for future hypogonadism drugs, but a sponsor would still need to demonstrate that enclomiphene's cardiovascular profile is acceptable.

Updated CMC Standards

Manufacturing analytical methods have advanced considerably since 2015. Chiral HPLC and LC-MS/MS methods now exist that can reliably separate and quantify enclomiphene and zuclomiphene at the levels the FDA requires [4]. A new sponsor with modern manufacturing infrastructure might clear the CMC hurdles that stopped Repros.

The Commercial Question

The compound itself is not patentable. Any NDA sponsor would need to rely on market exclusivity provisions (such as the 5-year new chemical entity exclusivity or 3-year new clinical investigation exclusivity) to justify the investment. With compounded enclomiphene already widely available, the commercial incentive to pursue approval is limited.

Comparison to Other SERMs in Male Hypogonadism

Enclomiphene is not the only SERM used off-label for male hypogonadism. Clomiphene citrate (Clomid) and tamoxifen are also prescribed, each with different regulatory standing.

Clomiphene citrate is FDA-approved for ovulation induction in women. Its use in men is entirely off-label. A 2019 meta-analysis of 15 studies (N=1,282) found that clomiphene citrate increased total testosterone by an average of 270 ng/dL in hypogonadal men, but the zuclomiphene component contributed to a longer wash-out period and higher rates of visual side effects [3].

Tamoxifen, FDA-approved for breast cancer, is occasionally used off-label for male hypogonadism at 10 to 20 mg daily. It raises testosterone through a similar hypothalamic mechanism but carries a distinct side effect profile including an elevated risk of venous thromboembolism [12].

Enclomiphene's theoretical advantage over both options is its cleaner pharmacological profile: pure estrogen antagonism at the hypothalamus without the long-acting estrogenic effects of zuclomiphene or the thromboembolic risks of tamoxifen.

International Regulatory Status

Enclomiphene citrate has not received marketing authorization from any major regulatory agency worldwide. It is not approved by the European Medicines Agency (EMA), the UK's Medicines and Healthcare products Regulatory Agency (MHRA), Health Canada, or Australia's Therapeutic Goods Administration (TGA). In some jurisdictions, including Australia and parts of Europe, compounding of enclomiphene is not permitted because the bulk substance has not been evaluated by the relevant national authority.

In India, several pharmaceutical companies market clomiphene citrate generics, but no company has sought approval for isolated enclomiphene. The regulatory pathway in India under the Central Drugs Standard Control Organisation (CDSCO) would require a separate clinical development program.